Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC)

Authors

B. Thapa
N. Henderson
S. T. Tagawa
Clara Hwang, Henry Ford HealthFollow
A. O. Sokolova
M. A. Bilen
P. M. Coelho Barata
C. B. Nguyen
A. Tripathi
A. Ayanambakkam
L. S. Graham
Y. Zakharia
V. S. Koshkin
E. Heath
T. B. Dorff
A. J. Armstrong
R. R. McKay
A. S. Alva
M. Schweizer
D. Kilari

Recommended Citation

Thapa B, Henderson N, Tagawa ST, Hwang C, Sokolova AO, Bilen MA, Coelho Barata PM, Nguyen CB, Tripathi A, Ayanambakkam A, Graham LS, Zakharia Y, Koshkin VS, Heath E, Dorff TB, Armstrong AJ, McKay RR, Alva AS, Schweizer M, Kilari D. Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC). Ann Oncol 2024; 35(S2):S991.

Document Type

Conference Proceeding

Publication Date

9-1-2024

Publication Title

Ann Oncol

PubMed ID

Not assigned.

Volume

35

Issue

S2

First Page

S991